Single, High-Dose Erythropoietin Given 2 Days Pre-Op Reduces Need for Transfused Blood, European Hospital Study
5/7/2013 7:49:34 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Anemia increases operative mortality and morbidity in non-cardiac and cardiac surgical procedures. Anemic surgical patients may require more blood transfusions, raising the risk of transfusion-related complications and increasing costs. For those reasons, optimizing patient readiness by correcting anemia prior to surgery is an important clinical goal. A simple new protocol has been proposed that helps correcting anemia using a single, high dose of recombinant human erythropoietin (HRE) administered only two days prior to surgery. The results of a randomized study will be presented by Luca Weltert, MD, Cardiac Surgery Department of the European Hospital in Rome, during the Plenary Scientific Session of the 93rd AATS Annual Meeting in Minneapolis.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by